Host-Tumor Interactions Research Program
Tumor growth, invasion, and metastasis depend not only on the tumor cell alone, but also on the complex interactions between the cancer, stromal, and immune cells. The goal of the Host-Tumor Interactions Research Program is to develop a detailed and mechanistic understanding of the complex cell and microenvironment in which cancer cell interact, and how these interactions influence cancer therapies and immunotherapies.
With the goal of understanding how complex interactions between tumor cells and their host contribute to cancer, the Host-Tumor Interactions program focuses on three specific research themes:
Inflammation & Immunity
Uncovering basic immune regulatory mechanisms in anti-tumor immunity and how inflammation can be exploited to eliminate cancer or can trigger and promote tumors
Tumor Systems Biology
Establishing single cell biology and modeling approaches to assess the composition and roles of the heterogeneous cell populations in tumor progression or therapeutic responses.
Tumor Imaging & Metabolism
Integrating and developing molecular imaging technologies to understand and monitor how tumors evolve in a changing microenvironment
Meet the Program Members
The Host-Tumor Interactions program is co-led by Mary M. Zutter, M.D., and Jeffrey Rathmell, Ph.D. The basic, translational, and clinical scientists who make up this program are focused on discovering and understanding these interactions, with the ultimate goal of developing strategies to control tumor progression and metastasis by targeting these interactions.
Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8 T cells and impede CAR T-cell efficacy.
van Bruggen, J.A.C., Martens, A.W.J., Fraietta, J.A., Hofland, T., Tonino, S.H., Eldering, E., Levin, M.D., Siska, P.J., Endstra, S., Rathmell, J.C. (HT), June, C.H., Porter, D.L., Melenhorst, J.J., Kater, A.P. & van der Windt, G.J.W.
Blood 134(1):44-58, 2019; PMID:31076448.
Size matters in nanoscale communication.
Zijlstra A (HT), Di Vizio D.
Nat. Cell Biol. 2018 MAR 20(3):228-230 PMID:29476154
Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models.
Schulte ML, Fu A, Zhao P, Li J, Geng L, Smith ST, Kondo J, Coffey RJ (GI), Johnson MO, Rathmell JC (HT), Sharick JT, Skala MC, Smith JA, Berlin JD (GI, TR), Washington MK (GI), Nickels ML, Manning HC (HT).
Nat. Med. 2018 FEB 24(2):194-202 PMC5803339
Similarities and Distinctions of Cancer and Immune Metabolism in Inflammation and Tumors
Andrejeva G, Rathmell JC (HT)
Cell Metab. 2017 JUL 5 26(1):49-70 PMC5555084.
Metabolic Regulation of the Immune Humoral Response
Boothby MR (HT), Rickert RC.
Immunity 2017 MAY 16 46(5):743-755 PMC5640164
Foxp3 and Toll-like receptor signaling balance Treg cell anabolic metabolism for suppression.
Gerriets VA, Kishton RJ, Johnson MO, Cohen S, Siska PJ, Nichols AG, Warmoes MO, de Cubas AA, MacIver NJ, Locasale JW, Turka LA, Wells AD, Rathmell JC (HT).
Nat. Immunol. 2016 DEC 17(12):1459-1466 PMC5215903.